Request Trial
31 August 2017Big Pharma

Video interview: Predicting Brexit’s life sciences impact

The practical implications of Brexit, including on the Unified Patent Court (UPC), were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
Novo Nordisk and OpenAI strike AI deal to boost drug discovery
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

More features

LSD trade secrets suit over clinical trail info thrown out by judge
HGF expands European offering with pair of in-house hires
What’s at stake in Australia’s biggest pharma patent appeal in years?
Vinson & Elkins grows West Coast patent and trade secrets bench
Will Mounjaro and Zepbound get their first US generic rival?
King & Spalding continues hiring spree from pre-merged Winston
Ashurst Perkins Coie opens its doors following landmark merger
Merck KGaA agrees $11.3bn deal in major life sciences expansion